On November 4, 2022 ENB Therapeutics, Inc., a biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor (ETBR) inhibitor, reported that it will present a scientific poster on ENB-003 at the 2022 Summit for Cancer Immunotherapy in Montreal, Quebec November 19-21, 2022 (Press release, ENB Therapeutics, NOV 4, 2022, View Source [SID1234634069]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Title: ENB-003, an ETBR inhibitor, in combination with pembrolizumab for advanced refractory solid tumors: (Download PDF)
Poster number: 143
Presenter: Sumayah Jamal, MD-PhD
Date: Sunday, November 20, 2022
Location and Time: 4:15 – 6:15 pm in Square Dorchester
About the Summit for Cancer Immunotherapy
Summit4CI 2022 is taking place in Montréal, Quebec, at the Fairmont the Queen Elizabeth. The conference will explore the latest progress in cancer immunotherapy from scientific, clinical, industry and patient perspectives during BioCanRx’s sixth scientific conference. This year’s keynote speaker is Dr. Carl June. To learn more, go to: View Source
About ENB-003
ENB-003 is a selective endothelin B receptor (ETBR) inhibitor that, in preclinical studies, enhanced the efficacy of immunotherapies such as anti-PD-1, anti-CTLA-4 and CAR T across multiple cancer types in preclinical studies. In an ongoing multi-center Phase 1/2 clinical trial, early efficacy signals suggest that ENB-003 overcomes resistance to the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in heavily pre-treated drug resistant cancer patients. The Phase 2 portion of the ENB-003 + pembrolizumab combination study is expected to start in the first quarter of 2023. The trial will enroll melanoma patients with innate resistance to anti-PD-1 based immunotherapies, platinum refractory and platinum resistant ovarian cancer patients, as well pancreatic cancer patients that have failed standard of care.